TY - JOUR
T1 - Eosinophilic Esophagitis
T2 - Etiology and Therapy
AU - Patel, Ronak V.
AU - Hirano, Ikuo
AU - Gonsalves, Nirmala
N1 - Funding Information:
Dr. Nirmala Gonsalves serves on the advisory board for Allakos and receives royalties from Up to Date. Dr. Ronak V. Patel has nothing to disclose. Dr. Ikuo Hirano has served as a consultant for Adare, Allakos, Arena, AstraZeneca, EsoCap, Gossamer, Receptos, Regeneron, and Shire Pharmaceuticals. He has received research funding from Adare, Allakos, Receptos, Regeneron, and Shire Pharmaceuticals.
Publisher Copyright:
© 2021 by Annual Reviews. All rights reserved.
PY - 2021/1/27
Y1 - 2021/1/27
N2 - Eosinophilic esophagitis (EoE) is a relatively recently identified but now frequently encountered antigen/immune-mediated disease which places significant burden on patients and the healthcare system. With its growing prevalence and recognition by healthcare providers in multiple disciplines, substantial progress has been made regarding the diagnostic criteria, clinical evaluation, tools for disease assessment, and immune pathways related to pathogenesis. Current treatment goals focus on the amelioration of inflammation and prevention of remodeling consequences using proton pump inhibitors, swallowed topical steroids, elimination diets, and esophageal dilation. Ongoing research holds promise for more efficacious and targeted therapies as well as a personalized approach to the care of patients with EoE.
AB - Eosinophilic esophagitis (EoE) is a relatively recently identified but now frequently encountered antigen/immune-mediated disease which places significant burden on patients and the healthcare system. With its growing prevalence and recognition by healthcare providers in multiple disciplines, substantial progress has been made regarding the diagnostic criteria, clinical evaluation, tools for disease assessment, and immune pathways related to pathogenesis. Current treatment goals focus on the amelioration of inflammation and prevention of remodeling consequences using proton pump inhibitors, swallowed topical steroids, elimination diets, and esophageal dilation. Ongoing research holds promise for more efficacious and targeted therapies as well as a personalized approach to the care of patients with EoE.
KW - Eosinophilic esophagitis
KW - dysphagia
KW - eosinophilic gastrointestinal disease
KW - esophageal dilation
KW - esophageal stricture
KW - gastroesophageal reflux disease
UR - http://www.scopus.com/inward/record.url?scp=85100216758&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100216758&partnerID=8YFLogxK
U2 - 10.1146/annurev-med-052819-023848
DO - 10.1146/annurev-med-052819-023848
M3 - Review article
C2 - 33228437
AN - SCOPUS:85100216758
SN - 0066-4219
VL - 72
SP - 183
EP - 197
JO - Annual Review of Medicine
JF - Annual Review of Medicine
ER -